Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912379676> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2912379676 abstract "Purpose: The purpose of this article is to compare the fellow-eye effect of unilateral intravitreal antivascular endothelial growth factor (anti-VEGF) treatment (bevacizumab, ranibizumab, and aflibercept) in patients with bilateral diabetic macular edema (DME). Methods: A retrospective review was conducted of hemoglobin A1c-matched groups receiving unilateral anti-VEGF injections (1.25 mg bevacizumab, 0.5 mg ranibizumab, and 2 mg aflibercept) in which the second eye had subclinical DME. Two main outcome measures evaluated were central subfield thickness (CST) on optical coherence tomography and best-corrected visual acuity (BCVA). Patients were excluded if they had poor BCVA (< 20/100) or had received laser, vitrectomy, filtering surgery, or pharmacologic treatments in the 3 months prior in the noninjected eye. Results: A total of 2073 total intravitreal anti-VEGF injections for DME were reviewed and 94 met the inclusion criteria: 40 bevacizumab, 33 ranibizumab, and 21 aflibercept. At 1 month, the CST of the fellow eye in the bevacizumab group had a statistically significant decrease (296.82 µm to 292.46 µm, P = .01) while both the ranibizumab and aflibercept groups trended toward worsening edema. When compared to ranibizumab and aflibercept, the CST in the noninjected eye in the bevacizumab group had improvements of –15.03 µm and –13.47 µm, respectively ( P < .019). When bevacizumab was switched to ranibizumab or aflibercept, the edema in the fellow eye worsened by +49.60 µm and +5.50 µm, respectively. Conclusion: Bevacizumab injection has a statistically significant therapeutic effect in the fellow eye when compared to those treated with ranibizumab and aflibercept. The edema in the fellow eye worsened when injection in the primary eye was switched away from bevacizumab." @default.
- W2912379676 created "2019-02-21" @default.
- W2912379676 creator A5011663331 @default.
- W2912379676 creator A5012851469 @default.
- W2912379676 creator A5034065706 @default.
- W2912379676 creator A5082439857 @default.
- W2912379676 creator A5086544825 @default.
- W2912379676 date "2019-02-01" @default.
- W2912379676 modified "2023-09-26" @default.
- W2912379676 title "Comparative Eye Effect of Unilateral Intravitreal Bevacizumab, Ranibizumab, and Aflibercept for Diabetic Macular Edema" @default.
- W2912379676 cites W1991409385 @default.
- W2912379676 cites W2007419896 @default.
- W2912379676 cites W2014268224 @default.
- W2912379676 cites W2022819203 @default.
- W2912379676 cites W2026686158 @default.
- W2912379676 cites W2067380467 @default.
- W2912379676 cites W2072011053 @default.
- W2912379676 cites W2083538148 @default.
- W2912379676 cites W2091597300 @default.
- W2912379676 cites W2096547439 @default.
- W2912379676 cites W2141737497 @default.
- W2912379676 cites W2145550059 @default.
- W2912379676 doi "https://doi.org/10.1177/2474126418819059" @default.
- W2912379676 hasPublicationYear "2019" @default.
- W2912379676 type Work @default.
- W2912379676 sameAs 2912379676 @default.
- W2912379676 citedByCount "1" @default.
- W2912379676 countsByYear W29123796762019 @default.
- W2912379676 crossrefType "journal-article" @default.
- W2912379676 hasAuthorship W2912379676A5011663331 @default.
- W2912379676 hasAuthorship W2912379676A5012851469 @default.
- W2912379676 hasAuthorship W2912379676A5034065706 @default.
- W2912379676 hasAuthorship W2912379676A5082439857 @default.
- W2912379676 hasAuthorship W2912379676A5086544825 @default.
- W2912379676 hasConcept C118487528 @default.
- W2912379676 hasConcept C134018914 @default.
- W2912379676 hasConcept C141071460 @default.
- W2912379676 hasConcept C2776694085 @default.
- W2912379676 hasConcept C2777802072 @default.
- W2912379676 hasConcept C2778257484 @default.
- W2912379676 hasConcept C2778749236 @default.
- W2912379676 hasConcept C2779829184 @default.
- W2912379676 hasConcept C2780347916 @default.
- W2912379676 hasConcept C2781100027 @default.
- W2912379676 hasConcept C2985127711 @default.
- W2912379676 hasConcept C555293320 @default.
- W2912379676 hasConcept C71924100 @default.
- W2912379676 hasConceptScore W2912379676C118487528 @default.
- W2912379676 hasConceptScore W2912379676C134018914 @default.
- W2912379676 hasConceptScore W2912379676C141071460 @default.
- W2912379676 hasConceptScore W2912379676C2776694085 @default.
- W2912379676 hasConceptScore W2912379676C2777802072 @default.
- W2912379676 hasConceptScore W2912379676C2778257484 @default.
- W2912379676 hasConceptScore W2912379676C2778749236 @default.
- W2912379676 hasConceptScore W2912379676C2779829184 @default.
- W2912379676 hasConceptScore W2912379676C2780347916 @default.
- W2912379676 hasConceptScore W2912379676C2781100027 @default.
- W2912379676 hasConceptScore W2912379676C2985127711 @default.
- W2912379676 hasConceptScore W2912379676C555293320 @default.
- W2912379676 hasConceptScore W2912379676C71924100 @default.
- W2912379676 hasLocation W29123796761 @default.
- W2912379676 hasOpenAccess W2912379676 @default.
- W2912379676 hasPrimaryLocation W29123796761 @default.
- W2912379676 hasRelatedWork W2176136391 @default.
- W2912379676 hasRelatedWork W2518773623 @default.
- W2912379676 hasRelatedWork W2578104864 @default.
- W2912379676 hasRelatedWork W2588011650 @default.
- W2912379676 hasRelatedWork W2739270759 @default.
- W2912379676 hasRelatedWork W2781132347 @default.
- W2912379676 hasRelatedWork W2912379676 @default.
- W2912379676 hasRelatedWork W2989968794 @default.
- W2912379676 hasRelatedWork W3175485016 @default.
- W2912379676 hasRelatedWork W4283759886 @default.
- W2912379676 isParatext "false" @default.
- W2912379676 isRetracted "false" @default.
- W2912379676 magId "2912379676" @default.
- W2912379676 workType "article" @default.